Tag Archives: RESI

RESI Innovators Shine in San Francisco – Winners Announced

12 Jan

Shaoyu Chang, MD, MPH, Director of Research & Asia Business Development Liaison

Shaoyu 10*10The third RESI San Francisco Conference event, held on January 10th, saw 30 Innovation Challenge finalists competing for the votes of the largest RESI crowd to date.  With 1,000 attendees present, more votes were cast than in any Innovation Challenge to date. Biotech, medical device, diagnostic and digital health companies all competed in the exhibition-style challenge for the top prize.  Selected from over 100 applicants, the 30 finalists included many phenomenal startups.  Here, LSN would like to present the 3 winners.

First Place: Pathcore (Toronto, Canada)

pathcore-500t

Pathcore brings innovation to the crossroads of pathology and computation. By leveraging the power of digital computing and algorithm-based image analysis, digital pathology has the potential to transform healthcare. Pathology is essential to the diagnosis and treatment of cancer and other diseases, as well as the discovery and evaluation of new treatments. Hundreds of millions of dollars are spent on cancer research every year, and Pathcore is focused on providing the tools to accelerate that research and translate it into applied solutions. Pathcore is committed to pathologists and the patients they serve. Our software solutions are designed by pathologists, for pathologists, to enable them to work together, share their knowledge and expertise, and be more accurate, effective, and efficient.

Michael Quigley, VP of Market Research, Life Science Nation | Dan Hosseinzadeh, CEO, Pathcore | George Ayd Assistant Vice President, Medmarc | Stephane Langevin, CCO, Pathcore

Second Place: Myndblue (Cambridge, MA)

myndblue-500

MyndBlue is a digital health/ connected medical device that detects and monitors relapse/recurrence in Major Depressive Disorders and Chronic PTSD. The company is headquartered in Paris and has US office in Cambridge, MA. MyndBlue’s mission is to change the way mental health conditions are diagnosed through technology, data and design – to get patients the right care. Mental health conditions affect around 615 million people worldwide. MyndBlue’s remote monitoring platform allows for a patient to be monitored with a proprietary device to provide information to a clinician before a crisis.

dsc05102

Michael Quigley, VP of Market Research, Life Science Nation | Denis Fompeyrine, PhD Founder & CEO, Myndblue | Nancy Briefs Serial Medical/Digital Health Entrepreneur, Myndblue | George Ayd Assistant Vice President, Medmarc

Third Place: Propep Surgical (Austin, TX)

propep-surgical-500

Sexual dysfunction and urinary incontinence are both common side effects following prostate cancer surgery. Inadvertent nerve injury occurring during the surgery is believed to be one of the primary causes. Using nerve monitoring technology that has been the Standard of Care in multiple surgical procedures for over 20 years, the ProPep® Nerve Monitoring System brings the same instant and accurate information regarding nerve location and function to laparoscopic and robotic prostatectomy surgery for the first time ever. The ProPep® Nerve Monitoring System is the first FDA-cleared real-time nerve monitoring system for laparoscopic & robotic prostatectomy surgery. With over 2500 commercial cases completed this system is proven to help surgeons identify critical non-visible somatic nerves at risk during surgery, thereby allowing the surgeon to make more-informed decisions on how to spare these nerves, potentially minimizing nerve damage.

Thank you to all who competed in the RESI San Francisco Innovation Challenge, and to all the RESI attendees who took part by investing their votes in their favorite competing companies.

Redefining Early Stage Investments Conference Series – San Francisco 2017 Program Guide Announced

5 Jan

By Nono Hu, Director of Marketing, LSN

LSN is looking forward to hosting the 11th Redefining Early Stage Investments Conference (RESI) during San Francisco’s annual healthcare conference week. At RESI, over 450 investors will be under one roof in search of compelling connections with early stage companies.

LSN would like to present the RESI San Francisco 2017 Program Guide. If you’re planning your day at RESI SF and want to see full lists of the investor panel speakers, RESI Innovation Challenge finalists and service providers you could meet, look no further!

resi-sf-program-guide-wp

Compelling New Technology Startups Selected RESI@JPM Innovation Challenge

29 Dec

By Dennis Ford, Founder & CEO, LSN

The 11th Redefining Early Stage Investments (RESI) Conference will be joining the JPM fray for our largest event yet on January 10th in San Francisco. We’re excited to announce the early stage life science companies that will be participating in the RESI Innovation Challenge.

The 30 participating companies have been hand-selected by LSN’s scientific review committee based on the innovative nature of their core technology and how well-positioned each is to capitalize on their respective market opportunities.

Therapeutics
 
Digital Health
 

Diagnostics
 

Medtech Devices
 

RESI San Francisco Panel Announcement: Tech Giants in Healthcare

29 Dec

By Michael Quigley, VP of Market Research, LSN

mike-2

Large technology companies have been expanding their footprint in the healthcare sector through venture investment and partnerships into early stage healthcare companies. Often seeking technology with a significant software component, many of these groups have helped to fuel the massive growth that has been seen in the digital health space in the past few years. From patient monitoring devices to mobile 3D imaging devices the lines between pure tech and healthcare are slowly beginning to blur as healthcare providers continually look to improve care while lowering costs.

Moderated by Michael Greeley, General Partner, Flare Capital Partners, the panelists are:

  • Iana Dimkova, Senior Associate, Healthcare, GE Ventures
  • Lucian Iancovici, FACHE, Head of Qualcomm Life Fund, Qualcomm Ventures
  • Rich Wilmot, Head of Corporate Venturing, Philips
  • Ying Tam, Head, Digital Health Cluster, Venture Services, MaRS

In this session, a number of investors at these large firms will discuss their involvement in healthcare innovation ecosystem. What types of technologies they are interested in? How much data do they like to see pre-investment? What problems in the space are they looking to tackle? These questions and more will be answered at RESI on Jan 10th so if you’re looking to partner with a large tech company for your product this is a panel you don’t want to miss.

RESI San Francisco Panel Announcement: Biotech Family Offices

15 Dec

By Lucy Parkinson, Director of Research, LSN

RESI has always aimed to represent the diversity of capital sources for early stage life science companies; alongside sessions featuring VCs, pharma, angels, and other traditional sources of capital, LSN is proud to feature two sessions devoted to Family Offices that invest in new healthcare ventures. The Biotech Family Office sesssion features investors from five different firms who will cover the wide-ranging interests of family offices in the early stage drug development sector.

Moderated by Jayson Rieger (SVP of Business Development & Portfolio Management, PBM Capital), the panelists are:

Christine Bunt (Venture Partner, 20/20 HealthCare Partners)
Will Eden (Vice President, Thiel Capital)
Daron Evans (Managing Director, PoC Capital)
Alex Pickett (Associate, Mediqventures)

If you’d be interested in hearing how these family offices source and assess biotech opportunities, and what you need to do to align your company with their investment ethos, you can register for RESI now.

resi-san-francisco-2017

RESI San Francisco Panel Announcement: Big Pharma

10 Nov

By Cole Bunn, Senior Research Analyst, LSN

cole-wp

As we gear up for the biggest RESI event of the year, during the heavily anticipated JPM week, we’re happy to once again announce the Big Pharma panel. This is typically one of the most popular panels at the RESI conference, and for good reason – large pharmaceutical and biotech companies, through a variety of deal structures, are looking earlier and earlier for assets, but tend to represent a daunting challenge for entrepreneurs seeking to successfully engage and navigate.

Senior-level executives from some of the world’s top pharmaceutical companies will provide some color around their process and strategy, and how entrepreneurs can best prepare to present to and work with organizations like theirs.

Big Pharma panelists will include the following:

  • Monica Viziano, Sr. Director, Business Development, Gilead
  • Barbara Sosnowski, VP External R&D Innovation, Pfizer
  • Lesley Stolz, Head, JLABS California, Johnson & Johnson Innovation
  • Christian Schubert, Director, Corporate Development & Strategy, Biogen
  • Jeremy Grunstein, Executive Director, Business Development, Amgen

By registering for RESI San Francisco on January 10 (Tuesday of JPM week), you’ll be able to listen to this panel live and gain insight into the dynamics of partnering with a strategic player as well as experience numerous opportunities to expand your network in the life sciences and learn more about the fundraising process in general.

resi-san-francisco-2017

Tips on How to Improve Your RESI Innovation Challenge Application – And Your Investor Pitch

3 Nov

By Christine A. Wu, Senior Research Analyst, LSN

chrsitine

The LSN Innovation Challenge is a competition held at every RESI Conference that provides early-stage companies with a unique opportunity to showcase their technologies at a meeting typically attended by 400 – 500 investors. LSN invites thirty top-tier early-stage fundraising companies to pitch their technologies in a poster format at a venue that provides ready access to a range of investors. The RESI Innovation Challenge has become an exciting event at each RESI meeting that attracts a lot of attention from entrepreneurs and investors alike.

The LSN scientific review team spends a lot of time reviewing applications, that now number in the hundreds, prior to selecting the top thirty. As the Innovation Challenge application deadline draws near (November 18th, folks!), we thought we would share with you how we select the winners. LSN’s scientific review team has compiled some tips on how to submit a compelling Innovation Challenge application.

Keep in mind that, while the following is focused on the Innovation Challenge application itself, the criteria and the tips we provide are also relevant for the fundraising process. Many of the questions we ask are similar to what investors will ask when you are out fundraising.

How do you achieve a high score on your application?

The LSN scientific review team uses a detailed rubric with a 200-point scoring system. Companies are stack-ranked on their scores and we invite the top 30 to present at RESI. Our evaluation process is based not only on scientific merit, but also on how ready the company is to present to an investor (“investor-readiness”). A high scoring company might have a transformational technology that can address a high unmet need using a novel approach or target. In addition to innovation, differentiation, unmet need, and market fit, investors are keenly interested in a broad IP position, an experienced management team and CEO with top-tier advisors, and strategic alliances with manufacturing and clinical partners (if the company is at that stage). LSN also looks at whether the company has “investor-ready” marketing material (executive summary, pitch deck, website).

Application Tips

Clearly describe your technology.

Like any marketing material, you need to be clear. Be sure to understand and answer the questions fully. Instead of saying “my company has a proprietary treatment for many critical illnesses”, it would be much clearer to say, “we are developing an IND-ready small molecule asset for breast cancer by activating natural killer cells.”

Lack of clarity will diminish your chances to participate in the Innovation Challenge.

Be realistic with your answers.

The team frequently reviews applications that don’t adequately highlight the competition. Novel products typically do have competitor’s products that precede them. The key point is to highlight how your technology differentiates itself from competitors.

For example, competitors for your disease-modifying therapeutic may only treat disease symptoms. You should identify existing therapeutics and highlight how your technology may offer a disease-modifying alternative.

Explain your current company status in detail.

Outline your current status, as well as provide your view of the strategic direction of your company. When describing your management team, avoid ambiguous statements such as, “CEO is an experienced entrepreneur”. Instead, provide details that highlight the CEO’s experience – years as an entrepreneur, number and names of companies exited, background expertise, etc.

Summarize near-term and long-term strategy.

If you do not have certain criteria, such as a strategic alliance or IP, it’s OK. State your current standing and provide what steps you are currently taking to reach that milestone.

For Alliances and Collaborations, summarize key relationships – focus on KOLs, medical centers, big pharma, and clinical and manufacturing partners. If there is no signed agreement, stating any verbal relationships would be helpful. If you don’t have issued patents yet, state how many patent applications you have filed or are planning to file. Providing us your strategy is better than a simple yes or no.

Provide enough information but don’t go over-board.

Spend more than 5 minutes on this application, but don’t spend 5 hours. Your answers should be brief, but reasonably detailed. We have received hastily done applications that lacked key information—which quickly received a low score and didn’t make the cut. The questions are all straight-forward that you should be comfortable in answering and have down pat. Remember, your executive summary should include answers to many of these questions already.

Send us your marketing material.

If you have marketing material, send it. We do read it and it can help your score. This includes your pitch deck, executive summary, website, videos – any supplemental material that can boost our understanding of your technology and whether your company is investor-ready. The application provides limited space. While this forces you to get straight to the point, supplemental material explains what an application sometimes doesn’t allow (i.e. figures, graphs, pipeline, non-confidential data, etc.)

Overall, applying for the Innovation Challenge is great practice for fundraising companies. For those who have yet to apply, be sure to take note of these suggestions and apply here before November 18th!

237521341025992000

resi-san-francisco-2017